Rain Enhancement Stock Price, News & Analysis

Rain Therapeutics Inc. (NASDAQ: RAIN), a late-stage precision oncology firm, is presenting at the IASLC 2021 World Conference on Lung Cancer from September 8-14, 2021. The poster, titled The MDM2/p53 axis is a therapeutic vulnerability in malignant pleural mesothelioma, will be presented by Dr. Lynn Heasley on September 8. Additionally, Avanish Vellanki will participate in a Targeted Oncology Panel at the Citi 16th Annual Biopharma Conference on September 10. Recordings will be available on the Rain website post-event.

Rain Therapeutics (RAIN) has initiated the Phase 3 MANTRA clinical trial for milademetan in patients with dedifferentiated liposarcoma, marking a significant milestone achieved under a year after acquiring the program. The company reported a quarter-end cash position of $164.6 million, ensuring funding through late 2024. Despite a net loss of $8.2 million for Q2 2021, up from $2.6 million in 2020, management remains optimistic about future trials and collaborations aimed at enhancing patient outcomes and anticipate interim results from their upcoming studies.

Rain Therapeutics Inc. (NasdaqGS: RAIN) is set to release its second-quarter financial results on August 10, 2021. The management will host a conference call at 1:30 PM PT to discuss the financial outcomes and business developments. Rain Therapeutics focuses on precision oncology therapies, utilizing a tumor-agnostic strategy to select patients based on genetic profiles, with its leading candidate being milademetan (RAIN-32), an MDM2 inhibitor. Investors and stakeholders can participate in the call via dial-in or a webcast link provided in the announcement.

Rain Therapeutics has announced the commencement of a Phase 3 trial (MANTRA) evaluating milademetan (RAIN-32) in patients with de-differentiated liposarcoma (DD LPS). This pivotal study, which aims to showcase the efficacy of milademetan against the standard treatment, trabectedin, is set to involve approximately 160 patients. Notably, previous studies show that patients have experienced long-term therapy for over 4 years with milademetan, indicating a favorable safety profile. The trial focuses on progression-free survival, aiming to fulfill a significant unmet medical need.

Rain Therapeutics Inc. has announced a partnership with Tempus to enhance its Phase 2 clinical trial for RAIN-32, targeting MDM2-amplified tumors. The trial is set to commence in the second half of 2021, focusing on utilizing Tempus' genomic analysis platform for patient matching and tumor profiling. RAIN-32, an oral MDM2 inhibitor, demonstrated significant anti-tumor activity in previous trials. The company plans to initiate a pivotal Phase 3 trial for liposarcoma and a Phase 2 tumor-agnostic basket trial later this year. RAIN-32 has already received FDA Orphan Drug Designation.

Rain Therapeutics has partnered with Caris Life Sciences to enhance patient referrals for its upcoming Phase 2 clinical trial of RAIN-32, an oral MDM2 inhibitor targeting cancers with MDM2 amplification. Set to begin in H2 2021, this novel trial will leverage Caris' molecular profiling technology to identify eligible patients across various solid tumors. Additionally, RAIN-32 has shown promising antitumor activity in prior studies, leading to plans for a pivotal Phase 3 trial in liposarcoma. The FDA has granted RAIN-32 Orphan Drug Designation, underscoring its potential.

Rain Therapeutics Inc. will be represented by CEO Avanish Vellanki at the Goldman Sachs 42nd Annual Global Healthcare Conference from June 8-11, 2021. He will present a corporate overview and engage in one-on-one investor meetings on June 10 at 5:30 p.m. ET. The presentation will be accessible via a webcast link and on the company's website. A replay will be available for 30 days following the event. Rain focuses on precision oncology, with its lead product RAIN-32 targeting MDM2 in various cancers.

Rain Therapeutics Inc. completed its IPO in April 2021, generating net proceeds of $121.9 million. The company plans to initiate a Phase 3 trial for RAIN-32 in well-differentiated/de-differentiated liposarcoma and an open-label Phase 2 basket trial for MDM2-amplified tumors, both set for 2H 2021. The first quarter results showed a net loss of $6.8 million compared to $2.6 million in Q1 2020, with R&D expenses significantly rising. Rain aims to end 2021 with a projected cash balance of $137 million to $147 million.

Rain Therapeutics has appointed co-founder Dr. Robert Doebele as president and chief scientific officer, enhancing its leadership as it approaches a critical Phase 3 clinical trial for RAIN-32. Dr. Doebele, an expert in precision oncology, will shape the company's strategy and operations. The leadership transition comes as Rain prepares for its Phase 3 trial for liposarcoma patients in late 2021. The company focuses on precision therapies that target oncogenic drivers, notably RAIN-32, an oral MDM2 inhibitor. Rain is positioned for growth following a recent IPO.